Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22229
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLoh, Zoe-
dc.contributor.authorMitchell, Paul L R-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorArulananda, Surein-
dc.date.accessioned2019-12-12T23:08:22Z-
dc.date.available2019-12-12T23:08:22Z-
dc.date.issued2019-12-
dc.identifier.citationInternal Medicine Journal 2019; 49(12): 1541-1545-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/22229-
dc.description.abstractFirst-line tyrosine kinase inhibitors are standard of care for non-small-cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c-ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of considering several other genomic aberrations in our population, such as rearrangements in the RET proto-oncogene, which occur in 1-2% of lung adenocarcinoma. New oncogenic drivers and corresponding targeted agents are constantly being discovered; these will continue to refine the treatment of non-small-cell lung cancer in the era of precision medicine.-
dc.language.isoeng-
dc.subjectRET rearrangement-
dc.subjectgenomic profiling-
dc.subjectnon-small-cell lung cancer-
dc.subjecttyrosine kinase inhibitor-
dc.subjectvandetanib-
dc.titleRET-rearranged non-small-cell lung cancer and therapeutic implications.-
dc.typeJournal Article-
dc.identifier.journaltitleInternal Medicine Journal-
dc.identifier.affiliationDepartment of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen
dc.identifier.doi10.1111/imj.14654-
dc.identifier.orcid0000-0002-9215-1441-
dc.identifier.orcid0000-0002-5636-6381-
dc.identifier.pubmedid31808254-
dc.type.austinJournal Article-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Feb 2, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.